Vitrolife AB (publ)
VTRLY · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.53 | 0.00 | -2.17 | 2.56 |
| FCF Yield | 1.00% | 0.79% | 0.28% | 0.95% |
| EV / EBITDA | 79.36 | 146.79 | 169.06 | 107.17 |
| Quality | ||||
| ROIC | 0.73% | 0.63% | 0.66% | 1.02% |
| Gross Margin | 51.02% | 57.98% | 57.36% | 61.11% |
| Cash Conversion Ratio | 2.47 | 1.14 | 0.49 | 1.47 |
| Growth | ||||
| Revenue 3-Year CAGR | -7.28% | 1.23% | 2.66% | 3.72% |
| Free Cash Flow Growth | -86.49% | 118.84% | -74.25% | 30.10% |
| Safety | ||||
| Net Debt / EBITDA | 3.54 | 7.82 | 5.98 | 3.52 |
| Interest Coverage | 11.92 | 27.40 | 15.10 | 5.23 |
| Efficiency | ||||
| Inventory Turnover | 0.94 | 0.85 | 0.87 | 0.88 |
| Cash Conversion Cycle | 136.00 | 140.20 | 145.92 | 124.82 |